Summary: Cytochrome P450 3A4 (CYP3A4) plays a crucial role in the pharmacokinetic and safety profiles of drugs. However, it is difficult to properly predict the pharmacokinetics and hepatotoxicity of drugs in humans using data from experimental animals, because the catalytic activities of CYP3A4 and other drugmetabolizing enzymes differ between human and animal organs. In order to easily generate an animal model for proper evaluation of human CYP3A4-mediated drug metabolism, we developed a human CYP3A4-expressing adenovirus (Ad) vector based on our novel Ad vector exhibiting significantly lower hepatotoxicity (Ad-E4-122aT-hCYP3A4). Intravenous administration of Ad-E4-122aT-hCYP3A4 at a dose of 2 © 10 11 virus particles/mouse produced a mouse exhibiting human CYP3A4 activity at a level similar to that in the human liver, as shown in the dexamethasone metabolic experiment using liver microsomes. The area under the curve (AUC) of 6¢OHD was 2.7-fold higher in the Ad-E4-122aT-hCYP3A4-administered mice, compared with the mice receiving a control Ad vector. This Ad vector-expressing human CYP3A4 would thus be a powerful tool for evaluating human CYP3A4-mediated drug metabolism in the livers of experimental animals.
Introduction
Foreign chemicals that enter the body are subject to metabolism by a number of xenobiotic-metabolizing enzymes, a process that functions primarily to facilitate their elimination. Cytochromes P450 (CYPs) are the most important of the enzymes responsible for the oxidative metabolism of a diverse range of foreign chemicals, including therapeutic drugs, carcinogens, toxicants, and endogenous compounds, such as steroid hormones and bile acids. 1, 2) In particular, the CYP1A, CYP2C, CYP2D, CYP2E1, and CYP3A subfamilies, which are mainly expressed in the liver, play central roles in the metabolism and disposition of drugs.
3) Furthermore, CYP-mediated metabolism of drugs is often involved in druginduced liver injury. 4) The evaluation of CYP-mediated metabolism of drugs is therefore crucial for the development of new drugs.
In the drug development process, the assessment of drug metabolic profiles in humans is largely based on the extrapolation of animal experiments to the human situation. Thus experimental animals, especially rodents, have been widely used as in vivo models to predict pharmacokinetics and toxicity in humans. However, the results obtained in in vivo studies using experimental animals do not always reflect the pharmacokinetics in humans. 5) It is now recognized that rodents metabolize drugs differently from humans, due in part to species differences in the expression and catalytic activities of CYPs in the organs. 6) Species differences in metabolite profiles present a challenge that may confound the nonclinical safety assessment of candidate drugs. 7, 8) When metabolites are formed uniquely or disproportionately in humans, FDA guidance suggests that the major metabolite(s) should be synthesized and tested in appropriate nonclinical safety assessment studies; 9) however, the synthesis of large amounts of metabolites is often problematic. 8) This bottleneck is an important one, since encountering major human metabolites in patients or study subjects that were not previously revealed in a nonclinical model can significantly hinder drug development.
In order to overcome the problem of the differential CYP enzyme profiles between humans and experimental animals, transgenic mouse lines carrying the specific human CYPs have been developed. [10] [11] [12] Human CYP-expressing mouse models may have the ability to generate major human metabolites and eliminate or reduce the formation of mouse-specific metabolites. When compared to the current strategy for handling metabolite challenges (i.e., direct administration of the metabolite), a number of advantages could be gained by the use of an appropriate human CYPexpressing animal model. 13) However, there are several problems with human CYP-expressing transgenic animals. For example, it is not possible to control the expression levels of the human CYPs. Multiple copies of human CYP expression cassettes are usually incorporated into the transgenic mouse genome, resulting in inappropriate levels of human CYP expression in the organs. 12) Unpredictable phenotypes are also found in human CYP-expressing animals. For example, human CYP3A4 transgenic mice exhibit a lactation defect caused by abnormal homeostasis of estradiol. 12) As a different approach to generating mice possessing human CYP activities, in vivo transduction with an adenovirus (Ad) vector seems promising because Ad vectors possess various advantages as gene delivery vehicles. 14, 15) In particular, the most attractive property of Ad vectors for use in the over-expression of human CYPs in the liver, which is the main organ for drug metabolism, is their high hepatotropism. More than 90% of the injected doses accumulate in the liver, resulting in substantially higher levels of transgene expression in the liver than in other organs. 16) However, Ad vector-mediated over-expression of human CYPs in rodent livers has not been successfully accomplished. Although Bai and Cederbaum demonstrated Ad vector-mediated over-expression of human CYP2E1 in the mouse liver, they did not evaluate the utility of the resulting strain as an animal model for analyzing drug metabolism in humans. 17) In addition, Ad vector-mediated overexpression of human CYP3A4, which is generally the most abundant hepatic and intestinal form, accounting on average for 95% of the combined liver CYP3A mRNA pool in Caucasians, 18, 19) and which is the CYP isoenzyme most highly involved in drug metabolism in humans, has not been reported in rodent livers.
In addition, there is an important concern in terms of Ad vectormediated over-expression of human CYPs in rodent livers. In vivo application of high doses of an Ad vector often induces severe hepatotoxicity due to Ad vector-induced innate immunity and leaky expression of Ad genes, 20) and such Ad vector-induced hepatotoxicity hampers the function analysis of the transduced genes. In order to overcome this problem, we used a novel Ad vector that exhibits extremely low levels of leaky expressions of all the Ad genes examined in the liver as well as a significantly reduced hepatotoxicity profile following intravenous administration into mice by incorporation of miR-122a-targeted sequences in the 3A-UTR of E4 genes. 21) This novel Ad vector was found to be suitable for gene function analysis in the liver.
In this study, in order to easily generate an animal model for the effective evaluation of human CYP3A4-mediated drug metabolism, we created a human CYP3A4-expressing Ad vector using a novel Ad vector that exhibits an apparent reduction in Ad vectormediated hepatotoxicity, and administered it to mice. In the present experiments, intravenous administration of the Ad vector expressing human CYP3A4 into mice resulted in animals with hepatic microsomal expression and activity of human CYP3A4 comparable to those in human liver microsomes without apparent Ad vector-mediated liver toxicity. This novel Ad vector expressing human CYP3A4 would thus be a powerful tool for evaluating human CYP3A4-mediated drug metabolism in the livers of experimental animals.
Materials and Methods
Chemicals and enzymes: Dexamethasone and midazolam were obtained from Wako Pure Chemicals (Osaka, Japan). 6¢-Hydroxydexamethazone was purchased from Toronto Research Chemicals Inc. (Toronto, Canada). Pooled human liver microsomes (H0610) were obtained from Xenothech, LLC (Lenexa, KS). Human liver cDNA was obtained from Takara Bio (Shiga, Japan). The NADPH-regenerating system used for all NADPH-requiring oxidase assays was purchased from BD Gentest (Woburn, MA). The system consists of two solutions, solution A (26.1 mM NADP + , 66 mM glucose-6-phosphate, and 66 mM MgCl 2 in H 2 O) and solution B (40 U/mL glucose-6-phosphate dehydrogenase in 5 mM sodium acetate).
Mice and cells: Female C57BL/6J mice aged 7 weeks were obtained from Nippon SLC (Hamamatsu, Japan). HepG2 cells (a human hepatocellular liver carcinoma cell line) and 293 cells (a human embryonic kidney cell line) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and antibiotics.
Plasmids and Ad vectors: Ad vectors were prepared by an improved in vitro ligation method. 22) Briefly, the human CYP3A4 gene was cloned into pHMCA5, 23) creating pHMCA5-hCYP3A4. The human CYP3A4 gene was amplified by PCR using cDNA derived from human liver cDNA and the following primers: hCYP3A4-F, 5A-CGAATCGTAGGGGTACCACCATGGCT-CTCATCCCAGACTTGGCCATGG-3A; hCYP3A4-F, 5A-CGA-ATCGTACCGCTCGAGTTATCAGGCTCCACTTACGGTGC-CATCCCTTG-3A. I-CeuI/PI-SceI-digested pHMCA5-hCYP3A4 was ligated with the I-CeuI/PI-SceI-digested Ad vector plasmid pAdHM4-E4-122aT, 21) producing pAdHM4-E4-122aT-hCYP3A4.
pAdHM4-E4-122aT contains an E1/E3-deleted Ad vector genome and four copies of miR-122a-targeted sequences in the 3A-untranslated region of the E4 gene. pAdHM4-E4-122aT-hCYP3A4 was digested with PacI to release the recombinant viral genome, and was transfected into 293 cells plated on 60-mm dishes. Ad vectors were propagated in 293 cells, purified by two rounds of cesium chloride-gradient ultracentrifugation, dialyzed, and stored at ¹80°C. The numbers of virus particles (VPs) were determined using a spectrophotometric method. 24) Ad-E4-122aT-GFP, which is a control Ad vector expressing green fluorescence protein (GFP), was similarly prepared using pHMCA5-GFP and pAdHM4-E4-122aT.
Measurement of CYP3A4 activity in HepG2 cells transduced with Ad-E4-122aT-hCYP3A4: HepG2 cells (3 © 10 5 cells/well) were seeded in 12-well plates. On the following day, the cells were transduced with Ad-E4-122aT-hCYP3A4 at a 100, 300, 1,000, and 3,000 VPs/cell. After a 48 h incubation, human CYP3A4 activity in the cells was measured according to the protocol included in the P450-Glo CYP3A4 Assay (Promega, Madison, WI).
Western blot analysis of human CYP3A4 in HepG2 cells and mouse liver microsomes: Total cell lysates prepared from HepG2 cells (20 µg) following Ad vector transduction were separated on 10% polyacrylamide gels. Mouse liver microsomes were prepared as described below 2 days after Ad vector administration. Mouse liver microsomal protein (2 µg) was similarly separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Human liver microsomes (2 µg) were used as a positive control. Samples were run at 20 mA for 1 h in 25 mM Tris buffer/0.2 M glycine/0.1% SDS buffer. Samples were then transferred to Immobilon-P (PVDF membrane; Millipore, Bedford, MA) for 2 h at 100 V in 25 mM Tris buffer/20% methanol. Blots were blocked with 5% skim milk for 1 h, and incubated with polyclonal goat anti-human CYP3A4 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) overnight. Subsequently, the blots were probed with the secondary antibody, mouse anti-goat IgGhorseradish peroxidase (1:5,000; Cell Signaling Technology, Beverly, MA) for 30 min. The bands were visualized by using an ECL Plus detection kit (GE Healthcare, Little Chalfont, UK).
Mouse liver microsome preparation: Ad vectors were intravenously administered into female C57BL/6J mice at a dose of 3 © 10 10 , 1 © 10 11 , or 2 © 10 11 VPs/mouse via the tail vein. The livers were harvested and homogenized with three volumes of ice-cold 0.1 mM phosphate buffer (pH 7.4) 2 days after Ad vector administration. Following the centrifugation of homogenates in a refrigerated centrifuge at 9,000 © g for 20 min at 4°C, the precipitate was discarded, and then 0.1 mM potassium phosphate buffer (pH 7.4) was added to the supernatant. The mixture was then centrifuged at 105,000 © g for 1 h at 4°C. The pellets of microsomes were resuspended in 0.1 mM potassium phosphate buffer (pH 7.4). The protein content was measured with a Bio-Rad assay kit (Bio-Rad, Hercules, CA) using bovine serum albumin as a standard. The microsomes were stored at ¹80°C until use.
Real-time reverse transcription PCR analysis: Total RNA from HepG2 cells was isolated using ISOGEN (Nippon Gene, Tokyo, Japan). mRNA levels of human CYP3A4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were quantified by real-time reverse transcription PCR using THUNDERBIRD SYBR qPCR Mix (TOYOBO, Osaka, Japan). The protocol for thermal cycling consisted of 60 s at 95°C, followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. The primer sequences used in this study were as follows: human CYP3A4, 5A-AAGGAAATCCACTCGG-TGCTT-3A and 5A-ATGAAAGAAAGTCGCCTCGAA-3A; human GAPDH, 5A-GGTGGTCTCCTCTGACTTCAAC-3A and 5A-GTGG-TCGTTGAGGGCAATG-3A.
Immunohistochemical analysis of human CYP3A4 expression in the mouse liver: The livers were harvested 2 days after Ad vector administration. The livers were then washed with cold phosphate-buffered saline (PBS) and embedded in optimal cutting temperature (OCT) for the frozen section (6 µm) preparation. The frozen sections were prepared using a Leica CM 1850 Cryostat (Leica Microsystems, Wetzlar, Germany) and fixed with acetone for 10 min at 4°C, followed by incubation for 30 min in 0.3% H 2 O 2 in methanol to quench the endogenous peroxidase activity. Sections were then blocked for 1 h with diluted normal blocking serum and incubated overnight with a polyclonal rabbit anti-human CYP3A4 antibody (1:100; BD Gentest, Woburn, MA). Sections were washed with PBS, and treated using a peroxidase-based avidin-biotin affinity system (Vector, Burlingame, CA). The liver sections were then visualized with 3,3A-diaminobenzidine tetrachloride (DAB) (Vector) as a chromogen, counterstained with haematoxylin, and observed under a microscope.
In vitro determination of the human CYP 3A4 activity in mouse liver microsomes: In vitro determination of human CYP3A4 activity in mouse liver microsomes was measured as previously described. 25) Briefly, a reaction mixture was prepared by mixing an NADPH-regenerating system (final concentrations: 1.3 mM NADP + , 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, and 3.3 mM MgCl 2 ) with 1 µM (final concentration) of midazolam and dexamethasone in 0.1 M potassium phosphate buffer (pH 7.4), and the mixture was pre-incubated at 37°C for 10 min. Then, 5 µL of liver microsomes (20 mg protein/ mL) was added, and the mixture was further incubated at 37°C for 30 min. Fifty µL of the mixture was harvested, and the reaction was stopped by addition of 100 µL of acetonitrile/ethanol (70/30 v/v%). The samples were centrifuged at 14,000 rpm for 3 min at 4°C, and the supernatants were subjected to LC-MS/MS analysis.
In vivo determination of the human CYP 3A4 activity in mice (pharmacokinetic experiments): Dexamethazone and midazolam (2 mg/10 mL) were dissolved in 8% well-solve (Celeste Corporation, Tokyo, Japan) solution. These compounds were orally administered to mice at a dose of 2 mg/kg at 48 h after Ad vector administration. At 10, 30, 60, 120, and 180 min, and 7 h after administration of the compounds, blood samples were taken from the inferior vena cava under anesthesia with isoflurane, and then the mice were sacrificed by cervical dislocation (n = 3 for each time point). One hundred µL of acetonitrile/ethanol (70/30 v/v%) was added to a 50 µL plasma sample, and mixed vigorously. The samples were centrifuged at 14,000 rpm for 3 min at 4°C, and the supernatants were subjected to LC-MS/MS analysis.
LC-MS/MS analyses: The LC-MS/MS system consisted of a Shimadzu Prominence HPLC system (Shimadzu, Kyoto, Japan) interfaced to an AB SCIEX 5000™ LC/MS/MS System. The system was controlled by Analyst 1.45.2 software (Applied Biosystems, Foster City, CA). Separation of parent compounds and metabolites was achieved by using a Shim-pack XR-ODSII 2.0 mm i.d. © 75 mm at a flow rate of 0.5 mL/min. The mobile phase included 0.1% formic acid (Buffer A) and acetonitrile (Buffer B). The gradient cycle used for metabolite identification consisted of an isocratic elution with 10% Buffer B for 0.5 min, followed by a linear increase of Buffer B to 90% from 0.5 to 2.5 min. The mobile phase was then maintained at 90% Buffer B for 3 min before being changed back to 10% at 3.01 min for a 4 min equilibration. The mass spectrometer was operated in positive mode for parent compound and metabolite measurement.
Estimation of pharmacokinetic parameters: The plasma concentrations of the compounds and metabolites in each group at the indicated time were given as an average (n = 3, each time point). The pharmacokinetic parameters for the parent compound and its metabolite were estimated from the plasma concentrationtime data by a noncompartmental approach using the program WinNonlin 6.1 (Pharsight, Mountain View, CA). The peak concentration in serum (C max ) and the corresponding time of maximum concentration (T max ) were obtained from the original data. The area under the serum concentration-time curve from time 0 to 420 min (AUC last ) was calculated by the trapezoidal rule and the AUC inf_obs with extrapolation to infinity by dividing the last measured concentration by . The elimination rate constant () was determined as the slope of linear regression for the terminal log-linear portion of the concentration versus time curve, and the elimination half-life (T 1/2 ) was calculated from 0.693/.
Statistical analysis: Statistical significance (p < 0.05) was determined using Student's t-test. Data are presented as means « S.D.
Results

Development of an Ad vector expressing human CYP3A4:
In order to introduce the human CYP3A4 gene into the mouse liver, an Ad vector expressing human CYP3A4 was developed because Ad vectors are known to possess strong hepatotropism (Fig. 1) . A CA promoter, which is a fusion promoter composed of the cytomegalovirus (CMV) enhancer and chicken ¢-actin promoter, 26) was selected for human CYP3A4 expression. A CA promoter is the most efficient promoter in the mouse liver. 27) In addition, an Ad vector possessing four copies of miR-122a-targeted sequences in the 3A-UTR of the E4 gene (Ad-E4-122aT) was used for delivery of the human CYP3A4 gene in order to avoid Ad vector-mediated hepatotoxicity. We previously demonstrated that Ad-E4-122aT exhibited a significant reduction in the leaky expression of Ad genes in the liver by miR-122a-mediated post-transcriptional silencing and Ad vector-mediated hepatotoxicity. 21) Apparent elevation in the serum AST and ALT levels, which is the representative hepatotoxicity marker, was not found 2 or 4 days following intravenous administration of Ad-E4-122aT-hCYP3A4 (data not shown).
Over-expression of human CYP3A4 in HepG2 cells: Next, in order to examine whether in vitro transduction with Ad-E4-122aT-hCYP3A4 up-regulates human CYP3A4 activity, human CYP3A4 mRNA, protein and activity levels were determined following transduction with Ad-E4-122aT-hCYP3A4 in HepG2 cells. Dose-dependent over-expression of human CYP3A4 was observed in HepG2 cells at the mRNA, protein and activity levels (Fig. 2) . These results indicate that Ad vector-mediated overexpression of human CYP3A4 conferred up-regulation of human CYP3A4 activity in vitro.
Human CYP3A4 protein and activity levels in the mouse liver following Ad vector administration: In order to determine the protein levels of human CYP3A4 in the livers of mice treated with Ad-E4-122aT-hCYP3A4, Western blot analysis was carried out. No human CYP3A4 expression was found in the livers of PBS-and Ad-E4-122aT-GFP-administered mice (Fig. 3A) . Human CYP3A4 protein levels were dependent on the dose of Ad-E4- Fig. 1 . Structure of the Ad vectors used in this study A GFP expression cassette was inserted into the E1-deleted region in Ad-E4-122aT-GFP. A human CYP3A4 expression cassette was inserted into the E1-deleted region in Ad-E4-122aT-hCYP3A4. CA, a fusion promoter composed of a CMV enhancer and chicken ¢-actin promoter; 122aT, miR-122a-targeted sequences; ITR, inverted terminal repeat. 122aT-hCYP3A4. Human CYP3A4 protein levels in the livers of mice treated with 2 © 10 11 VPs of Ad-E4-122aT-hCYP3A4 were comparable to those in the human liver microsomes. Human CYP3A4 expression levels were also evaluated by immunohistochemical staining of mouse liver sections following Ad vector administration. There were human CYP3A4-positive cells throughout the liver sections of mice treated with 2 © 10 11 VPs of Ad-E4-122aT-hCYP3A4 (Fig. 3B) . These results indicate that 2 © 10
11
VPs of Ad-E4-122aT-hCYP3A4 conferred to the mouse liver the ability to express human CYP3A4 protein levels comparable to those in human liver microsomes.
Next, to examine whether the human CYP3A4 protein expressed in the livers of Ad-E4-122aT-CYP3A4-administered mice was functional, mouse liver microsomes were prepared, and human CYP3A4 activities in the liver microsomes were evaluated 2 days after Ad vector administration. The concentration of 6¢-hydroxydexamethasone (6¢OHD) was measured for the determination of human CYP3A4 activity in the liver microsomes. Metabolism of dexamethasone to 6¢OHD is catalyzed mainly by human CYP3A4.
28) The rate of 6¢OHD formation by human liver microsomes is much higher than that in mouse liver microsomes. 29) As expected, only a small amount of 6¢OHD was formed in the liver microsomes of PBS-and Ad-E4-122aT-GFP-administered mice (Fig. 3C) . There was no increase in the formation of 6¢OHD in the livers of mice treated with 3 © 10 10 VPs of Ad-E4-122aT-CYP3A4 despite the significant expression of human CYP3A4 in the liver microsomes. However, the formation of 6¢OHD was approximately 4-and 7-fold increased in the liver microsomes of mice treated with Ad-E4-122aT-CYP3A4 at doses of 1 © 10 11 and 2 © 10 11 VPs/mouse, respectively. In particular, the levels of 6¢OHD formed in the liver microsomes of mice administered Ad-E4-122aT-CYP3A4 at a dose of 2 © 10 11 VPs/mouse were similar to those formed in humans. We also evaluated human CYP3A4 activity by measuring the metabolism of midazolam in the liver microsomes of mice treated with Ad-E4-122aT-CYP3A4. Midazolam is commonly used as a probe for CYP3A activity in humans, and is metabolized by CYP3A to its primary metabolite, 1A-hydroxymidazolam.
30) The formation of 1A-hydroxymidazolam was slightly but significantly increased (1.3-fold) in mice treated with Ad-E4-122aT-CYP3A4 at a dose of 2 © 10 11 VP/mouse, but not in mice treated with Ad-E4-122aT-CYP3A4 at doses of 1 © 10 11 or 3 © 10 10 VPs/mouse, compared with the mice receiving Ad-E4-122aT-GFP (Fig. 3D) .
Next, in order to examine the duration of human CYP3A4 activities in the mouse liver following Ad vector administration, human CYP3A4 activities in the mouse liver were assessed at 2, 4, 6, 8, and 14 days after administration of 2 © 10 11 VPs of Ad-E4-122aT-hCYP3A4. The highest human CYP3A4 activity was observed at 4 days after administration; the formation rate of 6¢OHD in the liver microsomes on day 4 was slightly but significantly higher than that in human liver microsomes (Fig. 4) . Human CYP3A4 activities in the mouse liver were maintained for at least 8 days after Ad-E4-122aT-hCYP3A4 administration. On day 14, although the formation rate of 6¢OHD was reduced by 50% compared with that on day 4, the level of human CYP3A4 activity in the mouse liver microsomes was still 63% of that in the human liver microsomes. These results indicate that human CYP3A4 activity comparable to that in human liver microsomes is maintained in the mouse liver for at least 8 days following intravenous administration of Ad-E4-122aT-hCYP3A4. In vivo pharmacokinetics profiles of human CYP3A4 substrates in mice over-expressing human CYP3A4: Next, in order to examine whether Ad vector-mediated over-expression of human CYP3A4 in the mouse liver alters the in vivo pharmacokinetics of human CYP3A4 substrates, dexamethasone and midazolam were orally administered to mice treated with Ad-E4-122aT-CYP3A4 at a dose of 2 mg/kg. Subsequently, the blood concentrations of dexamethasone, midazolam, and their metabolites were measured. The AUC of 6¢OHD in mice treated with Ad-E4-122aT-GFP was decreased by 72%, compared with that for the mice receiving PBS (Table 1) , probably due to the decline in endogenous metabolic activity in the liver by transduction with a high titer of the Ad vector in the liver, although there was no apparent difference in the formation rate of 6¢OHD between the liver microsomes of mice receiving PBS and those receiving Ad-E4-122aT-GFP, as shown in Figure 3C . The AUC of 6¢OHD was 1.4-fold and 2.7-fold elevated in mice treated with Ad-E4-122aT-hCYP3A4 at a dose of 3 © 10 10 VPs/mouse and 2 © 10 11 VPs/ mouse, respectively, compared with the mice receiving Ad-E4-122aT-GFP (Fig. 5B and Table 1 ). The T 1/2 of dexamethasone and the C max of 6¢OHD in mice receiving Ad-E4-122aT-hCYP3A4 were largely lower and higher than those in mice receiving Ad-E4-122aT-GFP, respectively ( Table 1) . These results indicate that Ad vector-mediated over-expression of human CYP3A4 in the mouse liver alters the in vivo pharmacokinetics of human CYP3A4-specific metabolites in mice. On the other hand, the AUCs for midazolam and the primary metabolite of midazolam, 1A-hydroxymidazolam, were not significantly different between the mice treated with Ad-E4-122aT-hCYP3A4 and Ad-E4-122aT-GFP (Figs. 5C, 5D and Table 2 ).
Discussion
In this study, we used an Ad vector to generate a human CYP3A4-expressing animal that could be used for the evaluation of drug metabolism in humans. For this purpose, a human CYP3A4-expressing Ad vector (Ad-E4-122aT-hCYP3A4) was generated using a novel Ad vector that exhibits a reduction in Ad vectormediated hepatotoxicity. A single administration of Ad-E4-122aT-hCYP3A4 to mice at dose of 2 © 10 11 VPs/mouse achieved levels of human CYP3A4 activity in the liver microsomes of the Ad-CYP3A4-administered mice that were similar to those in human liver microsomes. In addition, pharmacokinetic experiments revealed that the AUC of 6¢OHD was 2.7-fold elevated in the Ad-E4-122aT-hCYP3A4-administered mice, compared with the mice receiving a control Ad vector. To the best of our knowledge, this is the first report demonstrating the production of mice possessing hepatic activity of human CYP3A4 at levels similar to those in the human liver by the intravenous administration of an Ad vector expressing human CYP3A4, although several studies have reported that various types of human CYP activities are up-regulated in cultured cell lines, including HepG2 cells, by transduction with Ad vectors expressing human CYP enzymes. 31, 32) An Ad vector was used for over-expression of human CYP3A4 in the mouse liver in this study. An Ad vector was considered suitable for this purpose because Ad vectors are known to have strong hepatotropism. Several groups, including ours, have demonstrated that more than 90% of the injected dose of an Ad vector accumulates in the liver within several minutes following intravenous administration into mice. 16, 33, 34) Although transgenic animals expressing human CYP enzymes have been developed, [10] [11] [12] there remain several concerns with the resulting strains; the integration site and integrated copy numbers of the transgene cannot be adequately controlled, leading to unpredictable expression in transgenic mice. On the other hand, Ad vector-mediated over-expression of human CYP enzymes in the livers of experimental animals has several advantages for evaluating CYPmediated drug metabolism. First, human CYP enzyme activities in the liver can be easily controlled by altering the injected doses of an Ad vector. It is well known that CYP-mediated drug metabolism exhibits considerable interindividual variation, due in part to genetic polymorphisms. For example, in the case of human CYP2D6, which is known to be highly polymorphic, more than 100 Fig. 4 . Duration of human CYP3A4 activities in the mouse liver following Ad vector administration Human CYP3A4 activities in the mouse liver following Ad vector administration were assessed by measuring the formation rate of 6¢OHD in mouse liver microsomes. Ad-E4-122aT-hCYP3A4 was intravenously administered to mice at a dose of 2 © 10 11 VPs/mouse via the tail vein. The liver microsomes were prepared on the indicated days after Ad vector administration. Values are presented as the mean « S.D. (n = 3). ***p < 0.001, compared with mice treated with Ad-E4-122aT-GFP. Human liver microsomes (HLMs) were used as a positive control. allelic variants of CYP2D6 have been discovered to date (http:// www.cypalleles.ki.se/). 35) Five to 10% of Caucasians are poor metabolizers, resulting in individual variation in response to many drugs due to impaired metabolism by CYP2D6. 36) In human CYPpossessing animal models created by Ad vector administration, certain CYP poor and extensive metabolizer phenotypes are easily prepared by altering the Ad vector doses. Second, several types of human CYP enzymes can be simultaneously over-expressed by using an Ad vector possessing multiple human CYP genes. The combination of human CYP enzymes over-expressed in the liver can be modified by changing the human CYP genes in the Ad vector genome. Furthermore, Ad vectors are able to efficiently transduce the livers of various types of animals which are available for drug development studies, including mice, rats, dogs, and rabbits. [37] [38] [39] Due to these superior properties of Ad vectors as gene delivery vehicles, we concluded that an Ad vector would be suitable for the generation of experimental animals expressing human CYP genes in the liver.
In this study, there was no significant increase in the production of 6¢OHD in the liver microsomes derived from mice treated with Ad-E4-122aT-hCYP3A4 at a dose of 3 © 10 10 VPs/mouse, compared with mice treated with a control Ad vector, despite the apparent human CYP3A4 protein in the livers of mice administered Ad-E4-122aT-hCYP3A4 at a dose of 3 © 10 10 VPs/mouse in the Western blotting analysis (Figs. 3A and 3C) . Although there was no significant elevation of 6¢OHD formation in the liver microsomes of mice receiving 3 © 10 10 VPs of Ad-E4-122aT-hCYP3A4, we consider certain levels of CYP3A4 activity to have been present in the livers of mice even at the dose of 3 © 10 10 VPs/ mouse of Ad-E4-122aT-hCYP3A4; however, the levels of human CYP3A4 activity generated by 3 © 10 10 VPs of Ad-E4-122aT-hCYP3A4 would be much lower than the intrinsic 6¢OHD formation activity in the livers of mice treated with 2 © 10 11 VPs of Ad-E4-122aT-GFP, which would account for the lack of a statistically significant increase in 6¢OHD formation in the transduced liver microsomes, compared with the liver microsomes of mice treated with a control Ad vector. In this study, we used the Mice were intravenously administered with Ad-E4-122aT-hCYP3A4. Fortyeight hours after Ad vector administration, mice received midazolam (2 mg/kg) by oral administration. Values represent the mean (n = 3).
rate of 6¢OHD formation as a marker of human CYP3A4 activity. Although 6¢OHD is a human CYP3A4-specific metabolite of dexamethasone, 6¢OHD is slightly formed in the mouse liver microsomes (accounting for 5.8% of total metabolites formed) due to the endogenous mouse CYP activity in the liver. 29) In contrast, significant levels of human CYP3A4 activity were found even at 100 VPs/cell in HepG2 cells in this study. HepG2 cells, which are commonly used to evaluate hepatotoxicity induced by bioactivable compounds, showed almost undetectable CYP activities. 32) Thus, an Ad vector-mediated increase in human CYP3A4 enzymatic activity was clearly detected in HepG2 cells.
In this study, human CYP3A4 activity in the mouse liver was also evaluated by measuring the metabolism of midazolam; however, no significant increase in the formation of the primary metabolite of midazolam, 1-hydroxymidazolam, was observed in the mice receiving Ad-E4-122aT-hYCP3A4, compared with the mice treated with a control Ad vector in the in vivo pharmacokinetic experiments (Figs. 5C and 5D) , although slight but significant elevation of 1A-hydroxymidazolam formation was found in the liver microsomes of mice receiving 2 © 10 11 VP of Ad-E4-122aT-hCYP3A4 (Fig. 3D) . It remains unclear why midazolam metabolism did not appear to be increased in mice receiving Ad-E4-122aT-hCYP3A4; however, the in vitro metabolism experiment of midazolam using liver microsomes demonstrated that similar levels of 1A-hydroxymidazolam were produced in the liver microsomes of humans and PBS-treated mice, indicating that midazolam metabolic activities in the human and mouse liver are comparable. Mouse CYP3A and CYP2C metabolize midazolam to 1A-hydroxymidazolam. 40) Over-expressed human CYP3A4-mediated metabolism of midazolam might be lower than mouse endogenous CYP-mediated metabolism of midazolam. In a previous study, the human CYP3A4-transgenic mice and wild-type mice exhibited no significant difference in the metabolism of orally administered midazolam. 10) On the other hand, when midazolam was intravenously administered to human CYP3A4-transgenic mice that showed an approximately 2-fold higher human CYP3A4 expression in the liver than wild-type mice, a higher metabolism of midazolam was observed in the livers of human CYP3A4-transgenic mice, compared with wild-type mice.
11) Elevation of midazolam metabolism in vivo might be achieved by increasing the dose of Ad-E4-122aT-hCYP3A4, since higher doses of Ad-E4-122aT-hCYP3A4 mediate higher human CYP3A4 expression in the liver than is observed in the human liver. The findings described above also suggest that human CYP expression levels in experimental animals have a major effect on drug metabolism, and that it might be difficult to provide appropriate expression levels of human CYPs in transgenic animals. On the other hand, Ad vector-mediated human CYP expression levels in the organs can be easily controlled by increasing or decreasing the dose of an Ad vector. Recently, two studies demonstrated the development of human CYP3A4-humanizing transgenic mice and showed that these mice would be useful for evaluating human CYP3A4-mediated drug metabolism. 41, 42) The human CYP3A4-expressing mice in our present study possess mouse endogenous CYP activity, which might disrupt the evaluation of human CYP-mediated drug metabolism. Intravenous administration of an Ad vector expressing human CYP genes into mouse CYP gene-knockout mice would generate a better animal model for the evaluation of drug metabolism in humans, compared with wild-type mice receiving a human CYP gene-expressing Ad vector.
A novel Ad vector, in which four copies of sequences complementary to miR-122a, a liver-specific microRNA, are incorporated into the 3A-untranslated region of the E4 gene to suppress the leaky expression of Ad genes in the liver, was used for the overexpression of human CYP3A4 genes. We previously demonstrated that this Ad vector showed a significant reduction in the leaky expression of Ad genes in the liver and Ad vector-mediated hepatotoxicity. 21) This Ad vector was thus considered suitable for over-expression of human CYP3A4 in the liver. In order to confer to the mouse liver a level of human CYP3A4 activity comparable to that in the human liver microsomes, 2 © 10 11 VPs of an Ad vector expressing human CYP3A4 was required; however, intravenous administration of a conventional Ad vector expressing human CYP3A4 at such a high dose induced a significant increase in serum ALT levels 2 days after administration (data not shown). On the other hand, Ad-E4-122aT-hCYP3A4 did not induce any apparent hepatotoxicity. This property would also be advantageous for the evaluation of human CYP3A4-mediated drug metabolism.
In conclusion, we succeeded in the development of mice exhibiting hepatic activity of human CYP3A4 at levels similar to those in the human liver by intravenous administration of a novel Ad vector expressing human CYP3A4. This novel Ad vector expressing human CYP3A4 would be a powerful tool for evaluating human CYP3A4-mediated drug metabolism in the livers of experimental animals.
